PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for March 8, 2004 Subscribe to this News Feed    
 

High Tech Executive Pens Corporate Thriller To Help Fight Cancer

Kirch P. Andrews New Book Gains Worldwide Attention As 100 Percent of Proceeds go to Cancer Research

Austin, TX (PRWEB) March 8, 2004 ---High tech entrepreneur, Paul A. Kirchoff, a former Dell Computer and start-up veteran, has launched his first corporate thriller, Leapfrog", under the pen name Kirch P. Andrews. The novel, available exclusively at www.kirchpandrews.com, is a fast-paced, suspense ride that profiles the use of technology in speeding the drug discovery process as well as the moral and ethical issues that arise when science, technology and greed collide. The self-published book has already seen people from more than 65 countries help generate over $10,000 in donations in the first 21 days, making Leapfrog" one of the fastest selling self-published books in the industry. One hundred percent of the books proceeds will be donated to the National Foundation for Cancer Research (NFCR).

Kirchoff began the book in 1995 as a tribute to his father, a long-time pharmacist who died of a rare form of cancer before the novel was finished. Kirchoff went on to complete his MBA and enjoy a successful corporate career at Dell, United Devices and as CEO of his own start-up. The novel was eventually completed as a way to honor his fathers memory and to help fight all types of cancer, including the one that took the life of his father and may one day take his own.

We were very surprised and pleased that Paul contacted us with his intentions," said Dr. Sujuan Ba, Science Director for the NFCR. It is not every day that a successful executive spends eight years penning a novel and then decides to self-publish, devoting the entire effort to charity. That is why the book is getting such international attention and it will no doubt help propel our important research".

Fueled only by word of mouth, over 700 copies have already been sold and emails of support from cancer survivors and victims family members are pouring in. An intricate, addictive plot with twists and turns throughout. Worth every penny spent. A riveting story, a worthwhile cause... two great reasons to make sure you get this book and spread the word," said Richard Suweidan of Brooklyn, NY.

Drug discovery legend and Chairman of the University of Oxfords Chemistry Department, Dr. Graham Richards, wrote the books foreword stating in part, This novel highlights cutting-edge drug discovery techniques and places contemporary science in fast-paced, high-stakes fiction. His effort will make an impact." The website includes Professor Richards foreword as well as sample chapters and a background on the author.

Ive had modest success professionally but felt I needed to give something back to this world as a test of my own character and to honor my fathers memory," said author, Paul Kirchoff. I hope this effort and the books growing popularity serve as a catalyst for ground-breaking cancer research that may someday contribute to the cure."

Leapfrog" may be ordered directly from www.kirchpandrews.com. Books are $12.99 each with 100 percent of the proceeds going to the NFCR. When placing orders, visitors can elect to make an additional donation over the price of the book to the NFCR. The author will personally sign all books.

# # #

OPTIONS
Printer Friendly Version
Email this story to a colleague
CONTACT INFORMATION
Vanessa Mcmillan
512-692-4069
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.